Impact of antiphospholipid and antinuclear antibodies in coronary artery disease progression.

ABSTRACT:

Background/objectives

The role of antiphospholipid (aPL) and antinuclear antibodies (ANA) in the progression of coronary artery disease (CAD) remains uncertain. We aimed to determine whether the presence of aPL or ANA predicts CAD progression.

Methods

We conducted a retrospective, single-center, case-control study including patients with CAD classified as either rapid clinical progressors (RCP) or long-standing stable (LSS), and a population-based control group. Autoantibodies analyzed included anticardiolipin (aCL), anti-β2 glycoprotein I (aB2GPI), anti-phosphatidylserine/prothrombin (anti-PS/PT), and ANA.

Results

We included 180 CAD patients (58 RCP, 122 LSS) and 210 matched controls. CAD patients more frequently exhibited positive aCL (p<0.05), whereas aB2GPI IgA w

SUBMITTER: Garcia-Camarero T 

PROVIDER: S-EPMC12571853 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature